Tien Laboratory
About
We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.
Current Research
Some of the ongoing projects are focused on addressing following:
- Biomarker and genomic analyses with next generation sequencing (IvySeq) to provide personalized enrollment recommendation.
- Pharmacodynamic analysis to assess treatment response and target modulation.
- Understanding resistance mechanisms of targeted inhibitors underlying disease progression.
Lab Members
Read Bio
Siddhi Desai, PhDPostdoctoral Fellow
Read Bio
Hualin Zhang, PhDPostdoctoral Fellow
Read Bio
Jennifer MolloyResearch Technician
Read Bio
Inad RabadiResearch Technician
Publications
- Tien et al., A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. July 8, 2019.
- Griveau et al., A glial signature and Wnt7 signaling regulates glioma-vascular interactions and tumor microenvironment Cancer Cell April 19, 2018.
- Zhou et al., A sequentially priming phosphorylation cascade activates the gliomagenic transcription factor Olig2 Cell Reports April 18, 2017.
- Kupp et al., Lineage-restricted Olig2-RTK signaling governs the molecular subtype of glioma stem-like cells September 13, 2016.
- Tsai et al., Oligodendrocyte precursors migrate along vasculature in the developing nervous system. January 22, 2016.
- Yang et al., Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. August 9, 2012.
- Tien et al., Temporal-spatial regulation of astrocyte precursor cell proliferation by BRAF signaling in mammalian spinal cord. July 2012.
- Sun et al., Phosphorylation state of Olig2 regulates proliferation of neural progenitor. March 10, 2011.
Resources
JOB OPENINGS
Pharmacodynamics Technologist
The Ivy Brain Tumor Center is a non-conventional non-profit program offering state-of-the-art clinical trials for patients with the most aggressive form of brain cancer. It is home to the largest collection of Phase 0 trials for brain tumors in the world. Our multidisciplinary team of brain tumor specialists and scientists are accelerating drug discovery and precision medicine in neuro-oncology in an effort to identify the most promising first-in-class therapies for brain tumor patients.
Candidates with experience in preclinical studies are desirable. Prior experience in conducting molecular biology or genetic aassays and knowledge of signal transduction and oncogenic pathways is preferred.